India Glycols (500201) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 consolidated revenue from operations was ₹2,424.01 crore, EBITDA ₹129.48 crore and PAT ₹56.81 crore; 9M revenue was ₹6,850.30 crore, EBITDA ₹377.96 crore and PAT ₹166.90 crore.

• 9M growth was led by Bio-Fuel and Potable Spirits; BSPC had a weaker Q3, while Ennature Biopharma faced margin pressure.

• A proposed composite scheme would merge Kashipur Holdings and separate Potable Spirits, Bio-Fuel and Bio-Pharma businesses into focused entities.

Financial highlights

• Q3 consolidated revenue from operations rose to ₹2,424.01 crore from ₹2,118.94 crore; EBITDA was ₹129.48 crore vs ₹106.81 crore, and PAT ₹56.81 crore vs ₹41.63 crore.

• 9M consolidated revenue from operations increased to ₹6,850.30 crore from ₹5,882.46 crore; EBITDA was ₹377.96 crore vs ₹318.86 crore, and PAT ₹166.90 crore vs ₹130.78 crore.

• Standalone PAT was ₹43.84 crore in Q3 vs ₹37.79 crore; 9M standalone PAT was ₹130.03 crore vs ₹113.99 crore.

Segment performance

• Bio-Fuel Q3 revenue was ₹271.54 crore and segment result ₹8.84 crore; 9M revenue was ₹770.10 crore and result ₹40.78 crore.

• Potable Spirits Q3 revenue was ₹1,777.02 crore and segment result ₹73.26 crore; 9M revenue was ₹4,824.48 crore and result ₹178.03 crore.

• Bio-based Specialities and Performance Chemicals Q3 revenue was ₹325.38 crore and segment result ₹27.50 crore; 9M revenue was ₹1,087.89 crore and result ₹96.21 crore.

• Ennature Biopharma Q3 revenue was ₹50.07 crore and segment result ₹4.52 crore; 9M revenue was ₹167.83 crore and result ₹16.47 crore, with 9M EBIT down 48%.

• JV Q3 sales grew 12% and EBITDA rose 75%; 9M sales grew 13%, supported by lower feedstock costs and better product mix.